Mirko Unipan

Mirko Unipan

Auto-generated profile, based on publicly available information

Mirko Unipan

GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
VTVicki Trier Taasti
Vicki Trier Taasti
DHDjoya Hattu
Djoya Hattu
SPStephanie Peeters
Stephanie Peeters
ASAnke van der Salm
Anke van der Salm
JLJudith van Loon
Judith van Loon
RCRichard Canters
Richard Canters
Efficient workflows for adaptive proton therapy are of high importance. This study evaluated the possibility to replace repeat-CTs (reCTs) with synthetic CTs (sCTs), created based on cone-beam CTs (CBCTs), for flagging the need of plan adaptations in intensity-modulated proton therapy (IMPT) treatment of lung cancer patients. Forty-two IMPT patients were retrospectively included. For each patient, one CBCT and a same-day reCT were included. Two commercial sCT methods were applied; one based on CBCT number correction (Cor-sCT), and one based on deformable image registration (DIR-sCT). The clinical reCT workflow (deformable contour propagation and robust dose re-computation) was performed on the reCT as well as the two sCTs. The deformed target contours on the reCT/sCTs were checked by radiation oncologists and edited if needed. A dose-volume-histogram triggered plan adaptation method was compared between the reCT and the sCTs; patients needing a plan adaptation on the reCT but not on the sCT were denoted false negatives. As secondary evaluation, dose-volume-histogram comparison and gamma analysis (2%/2mm) were performed between the reCT and sCTs. There were five false negatives, two for Cor-sCT and three for DIR-sCT. However, three of these were only minor, and one was caused by tumour position differences between the reCT and CBCT and not by sCT quality issues. An average gamma pass rate of 93% was obtained for both sCT methods. Both sCT methods were judged to be of clinical quality and valuable for reducing the amount of reCT acquisitions.

11 January 2025 in Physica Medica
Verified
Journal Article
Closed access
VTVicki Trier Taasti
Vicki Trier Taasti
EKEsther Kneepkens
Esther Kneepkens
JSJudith van der Stoep
Judith van der Stoep
MVMarije Velders
Marije Velders
MCMaud Cobben
Maud Cobben
IRIlaria Rinaldi
Ilaria Rinaldi

26 November 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
DWDirk Wagenaar
Dirk Wagenaar
SHSteven J.M. Habraken
Steven J.M. Habraken
IRIlaria Rinaldi
Ilaria Rinaldi
DEDaniëlle B.P. Eekers
Daniëlle B.P. Eekers
MKMiranda Kramer
Miranda Kramer
ARAlejandra Méndez Romero
Alejandra Méndez Romero
Background and purpose: With proton therapy, the relative biological effectiveness (RBE) accounts for increased DNA damage caused by higher linear energy transfer (LET) compared to photons. However, the LET and hence the RBE varies along the proton range, particularly at the Bragg peak, introducing challenges in proton treatment planning for brain tumors. The aim of this paper is to standardize evaluating and reporting LET and RBE in proton therapy for patients with grade 2 and 3 IDH mutant gliomas among the Dutch proton therapy centers. Materials and methods: A working group, comprising experts from three Dutch proton therapy centers, conducted nine meetings between 2020 and 2023. A joint literature review supported the standardized evaluation and reporting of LET and RBE. Questionnaires sent out to the three Dutch proton centers in 2020 and 2023 provided input for discussions on clinical practices. Three clinical examples were chosen to illustrate the application of the recommended methodology in treatment planning. Results: Following the literature review, a guideline on evaluation and reporting using the dose averaged LET (LETd) of primary and secondary protons calculated in water normalized to unit density was established. The McNamara variable RBE model with an alpha/beta value of 2 Gy was selected for reporting. Conclusion: The study presents a harmonization of approaches to evaluating and reporting LET and variable RBE in a guideline for the three Dutch proton therapy centers, providing clarity for future clinical interpretation. Having chosen a single variable RBE model offers practicality, although its accuracy remains a topic of ongoing research.

24 June 2026 in Physics in Medicine & Biology
Verified
Journal Article
Open access
PDF file
GCGiorgio Cartechini
Giorgio Cartechini
EKEsther Kneepkens
Esther Kneepkens
GVGloria Vilches-Freixas
Gloria Vilches-Freixas
ILIndra Lubken
Indra Lubken
MVMarije Velders
Marije Velders
IRIlaria Rinaldi
Ilaria Rinaldi
Objective. Pencil beam scanning proton therapy is sensitive to respiratory motion, leading to potential dose inhomogeneities due to interplay effects. We developed and validated a predictive framework to assess interplay and motion robustness in lung and esophageal cancer patients treated under free-breathing conditions. Approach. A synthetic-breathing-based predictive model was implemented in the RayStation treatment planning system and validated against an a posteriori approach using patient-specific respiratory traces and machine log files. Both were benchmarked against the Monte Carlo engine FRED. To demonstrate the methodology, the framework was applied to two clinical cases treated on the Mevion S250i system without rescanning. Dose accumulation incorporated respiratory phase, range ( ± 3%), and setup ( ± 5 mm) uncertainties. Main results. Excellent agreement was observed between TPS and FRED ( < 1% mean dose difference) and between predictive and a posteriori models ( < 2 % across DVH metrics). Cumulative dose distributions for the primary CTV converged after five fractions, confirming robust delivery. Significance. This automated, clinically integrated framework enables pre-treatment prediction and a posteriori validation of interplay and motion robustness in Pencil beam scanning plans. Preliminary results support its clinical utility, especially for hypofractionation and targets with large motion ( > 2 cm). A larger cohort study is ongoing and will be reported separately.

30 October 2025 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
GVGloria Vilches‐Freixas
Gloria Vilches‐Freixas
VTVicki Trier Taasti
Vicki Trier Taasti
IRIlaria Rinaldi
Ilaria Rinaldi
MUMirko Unipan
Mirko Unipan
Background: CT simulation scan is typically used for proton therapy planning. However, non‐tissue‐like materials are often not correctly characterized by the CT conversion curve, and medical implants of high‐Z materials, such as metals, can introduce artifacts in CT images. These can negatively affect the accuracy of dose calculations, ultimately impacting both treatment planning and dose delivery. Purpose: To present our clinical procedures for managing implants in patients treated with proton therapy. Methods: We categorized implants into two groups—‘small’ and ‘large’—based on their size relative to the CT voxel and their effect on image quality. To assess the influence of different implants on dose calculations, we conducted dose evaluations in a few patients with different implants. Our key considerations included the selection of appropriate CT window‐level settings for implant contouring, the necessity of performing material overrides weighing the tradeoff between the time spent on contouring and the impact on the dose distribution, as well as artifact mitigation strategies. The proposed procedures were derived from these dose evaluations and our clinical experience. Results: For small implants, made of titanium or tantalum, we can rely on our CT conversion curves, without requiring material overrides. Conversely, larger implants, such as silicone breast implants, metal hip prostheses, or air pockets, require material overrides to ensure an accurate representation of stopping‐power ratios and to minimize dose discrepancies. The general rule is to avoid proton beams passing through metal implants when possible. Conclusions: We have presented a comprehensive and standardized strategy for managing implants in our routine clinical practice. These strategies have been specifically developed for our clinical setup based on pragmatic considerations and may not be universally applicable. However, we believe they can offer valuable insights for other proton therapy centers facing similar challenges and looking to enhance their protocols for implant management.

2 February 2026 in International Journal of Particle Therapy
Verified
Journal Article
Open access
GCGiorgio Cartechini
Giorgio Cartechini
FCFrancesco Giuseppe Cordoni
Francesco Giuseppe Cordoni
MUMirko Unipan
Mirko Unipan
IRIlaria Rinaldi
Ilaria Rinaldi
Accurate prediction of beam delivery time (BDT) is critical for operational efficiency, 4D dose calculations, and advanced proton therapy techniques. Despite its importance, no machine-specific BDT model exists for Mevion systems. We developed the first machine learning–based model for the Mevion S250i Hyperscan system. Institutional machine log files from 11 patients (1120 machine log files) were used to extract features describing spot position, energy layer changes, Adaptive Aperture (AA) movements, and spot charge. Inter-pulse time (ΔT) served as the target variable. A Random Forest model was trained with cross-validation and tested on held-out data. SHAP (SHapley Additive exPlanations) analysis quantified feature contributions. The model achieved mean absolute errors (MAE) ranging from 0.9 ms for short intervals (<50 ms) to 211 ms for long delays (>1000 ms). AA movements were the dominant global predictor for ΔT>50 ms, whereas spot positions and pulse charge dominated short intervals. Energy changes had a minor global influence but locally contributed to a large ΔT, consistent with range modulator physics. The model was tested on two clinically relevant applications: volumetric repainting beam sequence and 4D dose recalculation for interplay evaluation. The predicted cumulative delivery times deviated by only −1.6% from machine log files, and dosimetric metrics (D98, D95, and V95) remained within intrinsic delivery variability. This study presents the first machine learning–based BDT model for the Mevion S250i system, accurately capturing both predictive performance and machine-specific temporal dynamics. Explainable AI analysis using SHAP provided detailed insights into the operational characteristics of the system, highlighting the contributions of energy layer switching, AA adjustments, and spot position shifts to delivery time. The proposed BDT model demonstrated strong predictive performance across the clinical applications evaluated, supporting its potential use for interplay assessment, 4D dose calculation, and delivery time–based plan optimization.